We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Appeals court says some liability releases are ‘appropriate’ under US bankruptcy law
World’s biggest gene sequencing company rejects EU’s fast- track application
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
UK unveils reforms worth £650mn to boost the life sciences sector
Vote to remove John Thompson is the culmination of one of the largest shareholder activism campaigns in years
Government seeks to win over pharma groups with new investments in genomics research and drug manufacturing
As McDonald’s is targeted, governments also need to tighten and enforce rules
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Governments and some pharma companies try to tackle problem linked with drug resistance
Gene sequencing company heads for pivotal vote in battle with activist investor Carl Icahn
Human life appears to have an upper limit that has yet to be extended
Manufacturers racing to build what could be one of industry’s biggest markets must tread with care
Development chief raises worry over innovation after FTC sues to block Amgen-Horizon deal
The US trust buster’s opposition to the tie-up focuses on so-called pharmacy benefit managers
Also in today’s newsletter, investors look to the next health crisis on the horizon
Leonard Schleifer supportive of FTC’s lawsuit against takeover of Horizon Therapeutics
US regulator sues to block takeover of biotech group Horizon Therapeutics
Strong personal interest in healthcare among reasons for increase in flow of family office money into venture capital
Alzheimer’s advocates call for ambitious declaration to match the scope of commitments made 10 years ago
US biotech group is among coronavirus vaccine makers struggling with reduced demand post-pandemic
Shadow health secretary sets out plan to boost clinical research
Move will see the British healthcare start-up return to private ownership
One in 5 biomedical articles may contain faked data, with Chinese paper mills leading way
Proxy adviser says the two executives failed to take responsibility for destructive deal for Grail
Ascend is buying up manufacturing facilities from cash-strapped cell and gene therapy companies
UK Edition
